Australia · Delayed Price · Currency is AUD Racura Oncology Company Description
Racura Oncology Ltd, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments in Australia.
The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients.
It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.
It also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, the company investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein.
It has collaborations with Astex, MD Anderson, Sheba City of Health, University of North Carolina School of Medicine, University of Wollongong, and University of Newcastle.
The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025.
Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
| Country | Australia |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Daniel Tillett |
Contact Details
Address: Gateway, 1 Macquarie Place Sydney, NSW 2000 Australia | |
| Phone | 61 2 8051 3043 |
| Website | racuraoncology.com |
Stock Details
| Ticker Symbol | RAC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000RAC3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Tillett | Chief Executive Officer, MD and Director |
| Dr. Peter Michael Smith Ph.D. | Executive Chairman |
| Brendan Brown | Chief Financial Officer |
| Dr. Sophia Moscovis | Vice President of Operations and Strategy |
| Dr. Jose L. Iglesias M.D. | Chief Medical Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |